Skip to main content

A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.

Ono S, Oyama T, Lam S, Chong K, Foshag LJ, Hoon DS

Publication: Oncotarget (2015) • Vol 6 • Page 7053-64PMID: 25749524View on PubMed

Purpose

The purpose of this paper was to investigate if microRNA (miR, miRNA)-210 could be amplified directly from plasma without further purification and if miR-210 levels were correlated with disease stage and patient outcome. Levels of miR-210 in formalin-fixed paraffin-embedded (FFPE) primary tumor and metastasis were also compared.

Conclusion

Although miR-210 was amplifiable from plasma regardless of inclusion of a Centri-Sep purification after reverse transcription, the cycle threshold (CT) values were significantly higher when amplification was conducted directly on plasma without clean-up with Centri-Sep columns. Importantly, higher levels of miR-210 were found in plasma from patients with Stage III and Stage IV disease than in plasma from healthy patients and in plasma from stage IV patients than Stage III patients. miR-210 levels were also significantly higher in the plasma from disease-free melanoma patients than healthy controls and were associated with clinical recurrence, lower disease-free survival, and melanoma-specific survival. Importantly, unlike miR-210 levels in plasma, LDH levels were not a significant predictor of disease-free survival and offered no increased sensitivity over miR-210 levels alone. Levels of miR-210 were higher in lymph node and distant organ metastasis compared to the primary tumor.

Studies (1)

Purpose

The purpose of this study was to investigate if miR-210 could be amplified directly from plasma without further purification and if miR-210 levels were correlated with disease stage and patient outcome. Levels of miR-210 in formalin-fixed paraffin-embedded primary tumor and metastasis were also compared. Blood was collected in the initial study from six healthy donors and stage III (n=20) and IV (n=26) melanoma patients with current disease into sodium citrate tubes. To investigate differences in miR-210 levels in disease-free patients, sodium-citrate blood was collected from 35 healthy donors and 60 stage III and 70 stage IV disease-free melanoma patients. To investigate the association of miR-210 levels and disease-free survival, sodium-citrate blood was obtained at multiple timepoints including 13-95 days post-surgery from 88 stage III patients and segregated to 46 patients with reoccurrence <2 years after surgery and 42 patients with no reoccurrence >5 years after surgery. Blood was centrifuged at 1,300 × g for 10 min to obtain plasma and stored in liquid nitrogen. Proteins in plasma were deactivated and solubilized with Tween-20 and the specimen was centrifuged at 9,000 x g for 5 min and then purified with Centri-Sep 8-well strips kit before real-time PCR amplification of miR-210. FFPE specimens included primary tumors (n=21), metastasis from lymph node (n=43), lung (n=16), bowel (n=12), liver (n=6), distant skin (n=3), brain (n=2) and others (n=5) but no details of processing were included. RNA was extracted from ten 10 µm-thick sections, reverse transcribed using qScript cDNA Synthesis Kit, and quantified using the real-time PCR-based PerfeCTa microRNA Assay.

Summary of Findings

Although miR-210 was detectable in all specimens regardless of the inclusion of a Centri-Sep purification after reverse transcription, the CT values were significantly higher when amplification was conducted without use of a Centri-Sep column (P<0.001). Importantly, higher levels of miR-210 were found in plasma from patients with Stage III and Stage IV disease than in plasma from healthy patients (P=0.002 and P=0.001, respectively) and in plasma from stage IV patients than Stage III patients (P=0.008). miR-210 levels were also significantly higher in the plasma from disease-free melanoma patients than healthy controls (P<0.001). Using plasma direct amplification found increased miR-210 levels prior to clinical recurrence (P=0.012) and higher levels of miR-210 were associated with lower disease-free survival (P<0.001) and melanoma-specific survival (P<0.001). Importantly, unlike miR-210 levels in plasma LDH levels were not a significant predictor of disease free survival (P=0.081) and using a combination of LDH and plasma miR-210 levels was not a significantly better predictor of disease-free survival than miR-210 levels alone. miR-210 levels were higher in lymph node and distant organ metastasis compared to the primary tumor (P=0.002 and P<0.001, respectively).

  • Biospecimens

    FluidPlasma
    TissueSkin
    TissueLung
    TissueLiver
    TissueLymph Node
    TissueBrain
    TissueSmall Bowel
  • Preservation Types

    FrozenFormalin
  • Diagnoses

    Normal
    NeoplasticMelanoma
  • Platforms

    RNAReal-time qRT-PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Healthy
    Metastatic melanoma
    Stage III melanoma
    Stage IV melanoma
    Biospecimen AcquisitionBiospecimen location
    Distant metastasis
    Lymph node
    Primary tumor
    Analyte Extraction and PurificationAnalyte purification
    None
    Purified with Centri-Sep column after reverse transcription
    Real-time qRT-PCR SpecificTargeted nucleic acid
    miR-221
    Real-time qRT-PCR SpecificTemplate modification
    Not purified
    Purified with Centri-Sep